Your browser is no longer supported. Please, upgrade your browser.
Settings
SCMP Sucampo Pharmaceuticals, Inc. daily Stock Chart
SCMP [NASD]
Sucampo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.30 Insider Own0.10% Shs Outstand46.75M Perf Week-3.29%
Market Cap549.31M Forward P/E10.95 EPS next Y1.07 Insider Trans-97.72% Shs Float25.45M Perf Month3.98%
Income-153.20M PEG- EPS next Q0.26 Inst Own57.20% Short Float17.23% Perf Quarter12.98%
Sales247.10M P/S2.22 EPS this Y-42.20% Inst Trans-1.26% Short Ratio9.07 Perf Half Y7.31%
Book/sh0.57 P/B20.61 EPS next Y4.99% ROA-32.70% Target Price18.14 Perf Year-9.20%
Cash/sh- P/C- EPS next 5Y14.00% ROE-119.50% 52W Range9.30 - 17.55 Perf YTD-13.28%
Dividend- P/FCF14.69 EPS past 5Y24.80% ROI9.60% 52W High-33.03% Beta1.42
Dividend %- Quick Ratio4.40 Sales past 5Y33.30% Gross Margin73.20% 52W Low26.34% ATR0.39
Employees139 Current Ratio5.10 Sales Q/Q15.20% Oper. Margin-53.50% RSI (14)48.91 Volatility2.97% 3.30%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-62.00% Rel Volume0.35 Prev Close11.85
ShortableYes LT Debt/Eq11.08 EarningsNov 01 BMO Payout- Avg Volume483.53K Price11.75
Recom2.00 SMA20-2.64% SMA504.35% SMA2004.28% Volume171,073 Change-0.84%
Aug-21-17Upgrade Leerink Partners Mkt Perform → Outperform
Mar-10-17Reiterated WallachBeth Buy $20 → $15
Mar-09-17Reiterated Mizuho Buy $16 → $14
Mar-06-17Reiterated Mizuho Buy $16
Dec-22-16Upgrade Mizuho Neutral → Buy $16
Nov-15-16Reiterated Maxim Group Buy $17 → $19
Nov-14-16Reiterated Mizuho Neutral $13 → $16
Sep-07-16Initiated Northland Capital Outperform
Aug-04-16Downgrade Mizuho Buy → Neutral $13
Aug-01-16Reiterated Maxim Group Buy $26 → $17
May-05-16Upgrade WallachBeth Hold → Buy $16
Apr-20-16Upgrade Mizuho Neutral → Buy $14
Mar-10-16Reiterated WallachBeth Hold $27 → $16
Mar-09-16Reiterated Maxim Group Buy $25 → $26
Jan-15-16Reiterated Mizuho Neutral $19 → $14
Nov-20-15Initiated Jefferies Hold $19
Nov-13-15Reiterated Mizuho Neutral $22 → $19
Oct-29-15Resumed ROTH Capital Buy $29
Oct-09-15Initiated Mizuho Neutral
Sep-03-15Initiated Leerink Partners Mkt Perform
Sep-21-17 08:25AM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-20-17 04:15PM  Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel GlobeNewswire
Sep-19-17 04:15PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-13-17 08:20PM  ETFs with exposure to Sucampo Pharmaceuticals, Inc. : September 14, 2017 Capital Cube
Sep-11-17 02:33PM  Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube +6.07%
08:30AM  Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress Business Wire
Sep-08-17 03:56AM  Sucampo (SCMP) Up 17.1% Since Earnings Report: Can It Continue? Zacks
Aug-30-17 04:05PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-22-17 08:20AM  Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : August 22, 2017 Capital Cube
Aug-16-17 10:17PM  Sucampo Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCMP) : August 17, 2017 Capital Cube
Aug-13-17 12:55PM  Edited Transcript of SCMP earnings conference call or presentation 2-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-04-17 09:48AM  Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : August 4, 2017 Capital Cube
Aug-03-17 09:51AM  Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y Zacks
12:12AM  Sucampo reports 2Q loss Associated Press
Aug-02-17 06:30AM  Sucampo Reports Second Quarter 2017 Financial Results GlobeNewswire
06:20AM  Investor Network: Sucampo Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-19-17 04:05PM  Sucampo Announces Second Quarter 2017 Earnings Call GlobeNewswire
Jul-18-17 04:05PM  Dr. Karen Smith Joins Sucampos Board of Directors GlobeNewswire
Jul-11-17 02:59PM  ETFs with exposure to Sucampo Pharmaceuticals, Inc. : July 11, 2017 Capital Cube
Jul-05-17 05:22PM  Sucampo (SCMP) Remains Focused on Amitza Label Expansion Zacks
Jun-22-17 08:07AM  Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : June 22, 2017 Capital Cube
Jun-19-17 04:05PM  ETFs with exposure to Sucampo Pharmaceuticals, Inc. : June 19, 2017 Capital Cube
Jun-16-17 12:08PM  Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
12:02PM  3 Hiddem Gems in the Healthcare Sector Motley Fool
Jun-13-17 04:30PM  Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270 GlobeNewswire
Jun-07-17 04:04AM  Why Is Sucampo (SCMP) Up 1.5% Since the Last Earnings Report? Zacks
Jun-01-17 04:30PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-29-17 08:21AM  Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : May 29, 2017 Capital Cube
May-19-17 05:00PM  Edited Transcript of SCMP earnings conference call or presentation 3-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-15-17 08:30AM  Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors Marketwired
May-12-17 05:14PM  Sucampo Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCMP) : May 12, 2017 Capital Cube
May-11-17 04:05PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2017 Health Care Conference GlobeNewswire
08:26AM  Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : May 11, 2017 Capital Cube
May-06-17 07:40AM  Edited Transcript of SCMP earnings conference call or presentation 3-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-03-17 07:15AM  Investor Network: Sucampo Pharmaceuticals, Inc. to Host Earnings Call Accesswire
06:42AM  Sucampo tops 1Q revenue forecasts Associated Press
06:30AM  Sucampo Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-26-17 04:01PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
03:35PM  ETFs with exposure to Sucampo Pharmaceuticals, Inc. : April 26, 2017 Capital Cube
Apr-19-17 06:30AM  Sucampo Announces First Quarter 2017 Earnings Call GlobeNewswire
Apr-18-17 06:31AM  New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1 GlobeNewswire
Apr-10-17 04:01AM  Sucampo (SCMP) Down 7.6% Since Earnings Report: Can It Rebound? Zacks -7.44%
Apr-07-17 04:51PM  7 of the Worst-Performing Stocks in Gurus' Portfolios GuruFocus.com
Apr-03-17 10:20AM  Sucampo just bought this local rare disease company for $200M at bizjournals.com
10:20AM  Sucampo just bought this local rare disease company for $200M American City Business Journals
06:57AM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisiti
06:30AM  Sucampo Acquires Vtesse Inc. GlobeNewswire
Mar-28-17 04:01PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-16-17 05:50PM  Local drug company stocks react to Trump's proposed cuts to NIH, FDA at bizjournals.com
05:50PM  Local drug company stocks react to Trump's proposed cuts to NIH, FDA American City Business Journals
Mar-15-17 05:01PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Mar-14-17 01:04PM  SUCAMPO PHARMACEUTICALS, INC. Financials
10:11AM  Sucampo Pharmaceuticals (SCMP): Moving Average Crossover Alert Zacks
Mar-13-17 08:54AM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-09-17 10:54AM  Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 Capital Cube -6.64%
10:54AM  Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
10:53AM  Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed Zacks
Mar-08-17 10:20PM  Edited Transcript of SCMP earnings conference call or presentation 8-Mar-17 1:30pm GMT Thomson Reuters StreetEvents +7.11%
01:21PM  Here's Why Sucampo Pharmaceuticals Rose as Much as 13.3% Today at Motley Fool
10:08AM  Nasdaq Leads On Chips; Dow Dips As Caterpillar Off, Banks Up
09:11AM  Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics
08:30AM  Sucampo Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2016 Sucampo Pharmaceuticals Inc Earnings Release - Before Market Open
06:48AM  Sucampo tops 4Q revenue forecasts
06:36AM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors
06:30AM  Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-23-17 04:02PM  Sucampo Announces Fourth Quarter and Full Year 2016 Earnings Call GlobeNewswire
Feb-17-17 05:41PM  Sucampo Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb-16-17 04:25PM  Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
Feb-09-17 10:36AM  Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
06:30AM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Global Healthcare Conference GlobeNewswire
Feb-07-17 10:56AM  Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
Feb-06-17 08:19AM  Portola, HealthCare Royalty Partners Ink $150 Million Deal
Feb-03-17 08:06AM  AMAG Down Despite Positive Data on Makena Auto-Injector
Feb-02-17 09:49AM  Novartis (NVS) Votubia Gets EU Approval for Label Expansion
07:21AM  Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
Jan-31-17 10:45AM  Mylan (MYL) Gets Favorable Verdict for Copaxone in the US
Jan-30-17 04:19PM  Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
10:20AM  Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
Jan-27-17 02:42PM  AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag
09:05AM  Endo (ENDP) Restructures its Branded Pharmaceutical Unit
Jan-26-17 03:29PM  Celgene (CELG) Misses on Earnings & Revenues, Keeps View
Jan-23-17 05:26PM  Gilead (GILD) HCV Therapy Application Validated in Europe
05:22PM  Bristol-Myers Settles Litigation with Merck for Keytruda
08:28AM  Prima Biomed Initiates Randomized Study for Breast Cancer
Jan-19-17 09:04AM  Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
Jan-18-17 08:29AM  Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
08:26AM  Benitec Stock Up on Orphan Drug Status for BB-301 in EU
Jan-17-17 09:30AM  Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals -5.60%
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-16-17 08:16AM  4 Profitable Stocks with Amazingly High Returns
08:09AM  5 Top Ranked Stocks with Upgraded Broker Ratings to Buy Now
Jan-13-17 09:55AM  Coherus Offers Positive Phase III Data on Humira Biosimilar
Jan-12-17 04:19PM  TherapeuticsMD's Rejoice Study Data Published in Journal
08:43AM  Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
Jan-11-17 04:42PM  Valeant Streamlines Portfolio with Skincare Brands Sale
09:30AM  The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America
08:27AM  Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
Jan-10-17 06:03PM  5 Underperformers of 2016: Turnaround Story in 2017?
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company's marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ueno Ryuji10% OwnerSep 11Sale12.001,000,00012,000,0008,006,585Sep 13 05:50 PM
Kuno Sachiko10% OwnerSep 11Sale12.001,000,00012,000,0007,137,344Sep 13 05:50 PM
Getman Daniel PDirectorNov 29Option Exercise6.803,79925,8333,799Nov 30 04:01 PM
Greenleaf PeterCEONov 29Option Exercise6.7582,459556,59884,972Nov 30 04:01 PM
Greenleaf PeterCEONov 29Sale16.7582,4591,381,1882,513Nov 30 04:01 PM
Getman Daniel PDirectorNov 29Sale16.753,79963,6330Nov 30 04:01 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 28Option Exercise8.3324,975208,04228,424Nov 28 09:30 PM
Getman Daniel PDirectorNov 28Option Exercise6.8016,201110,16716,201Nov 30 04:01 PM
Greenleaf PeterCEONov 28Option Exercise6.75117,541793,402120,054Nov 30 04:01 PM
Greenleaf PeterCEONov 28Sale16.91117,5411,987,6182,513Nov 30 04:01 PM
Getman Daniel PDirectorNov 28Sale16.8916,201273,6350Nov 30 04:01 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 28Sale16.7324,975417,8323,449Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 25Option Exercise8.3399,025824,878102,474Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 25Sale15.8899,0251,572,5173,449Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 23Option Exercise8.3326,000216,58029,449Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 23Sale15.7726,000410,0203,449Nov 28 09:30 PM
Smith Andrew PChief Financial OfficerNov 15Sale15.581,76627,514348Nov 16 04:01 PM